Latest Blogs on Technology, Travel, Movies and Photo Gallery

Cullgen Announces First-In-Human Dose in Phase I/II Trial of CG001419, a First-in-Class TRK Protein Degrader for Treatment of Cancer Patients

CG001419 is Cullgenâ€™s first protein degrader to enter clinical development SAN DIEGO & SHANGHAI--(BUSINESS WIRE)--Cullgen…

3 years ago

VIENNA--(BUSINESS WIRE)--#worldbranding--The third instalment of the Animalis Edition at the 2023 - 2024 World Branding…

3 years ago

VIENNA--(BUSINESS WIRE)--#worldbranding--The third instalment of the Animalis Edition at the 2023 - 2024 World Branding…

3 years ago

VIENNA--(BUSINESS WIRE)--#worldbranding--The third instalment of the Animalis Edition at the 2023 - 2024 World Branding…

3 years ago

VIENNA--(BUSINESS WIRE)--#worldbranding--The third instalment of the Animalis Edition at the 2023 - 2024 World Branding…

3 years ago

VIENNA--(BUSINESS WIRE)--#worldbranding--The third instalment of the Animalis Edition at the 2023 - 2024 World Branding…

3 years ago

VIENNA--(BUSINESS WIRE)--#worldbranding--The third instalment of the Animalis Edition at the 2023 - 2024 World Branding…

3 years ago

VIENNA--(BUSINESS WIRE)--#worldbranding--The third instalment of the Animalis Edition at the 2023 - 2024 World Branding…

3 years ago

VIENNA--(BUSINESS WIRE)--#worldbranding--The third instalment of the Animalis Edition at the 2023 - 2024 World Branding…

3 years ago

QUZHOU, China--(BUSINESS WIRE)--On July 25, 2023, an activity for unveiling the international expression of Quzhou…

3 years ago